3 documents found, page 1 of 1
DNA damage in circulating leukocytes measured with the comet assay may predict ...
Bonassi, S; Ceppi, M; Møller, P; Azqueta, A; Milić, M; Neri, M; Brunborg, G; Godschalk, R; Koppen, G; Langie, SAS; Teixeira, JP; Bruzzone, MThe comet assay or single cell gel electrophoresis, is the most common method used to measure strand breaks and a variety of other DNA lesions in human populations. To estimate the risk of overall mortality, mortality by cause, and cancer incidence associated to DNA damage, a cohort of 2,403 healthy individuals (25,978 person-years) screened in 16 laboratories using the comet assay between 1996 and 2016 was fol...
The hCOMET project: International database comparison of results with the comet...
Milić, M; Ceppi, M; Bruzzone, M; Azqueta, A; Brunborg, G; Godschalk, R; Koppen, G; Langie, S; Møller, P; Teixeira, JP; Alija, A; Anderson, D; Andrade, VThe alkaline comet assay, or single cell gel electrophoresis, is one of the most popular methods for assessing DNA damage in human population. One of the open issues concerning this assay is the identification of those factors that can explain the large inter-individual and inter-laboratory variation. International collaborative initiatives such as the hCOMET project - a COST Action launched in 2016 - represent...
Atorvastatin versus Bezafibrate in Mixed Hyperlipidaemia : Randomised Clinical ...
Ros, E; Oliván, J; Mostaza, JM; Vilardell, M; Pintó, X; Civeira, F; Hernández, A; Marques da Silva, P; Rodriguez-Botaro, A; Zambón, D; Lima, JOBJECTIVE: Combined hyperlipidaemia is a common and highly atherogenic lipid phenotype with multiple lipoprotein abnormalities that are difficult to normalise with single-drug therapy. The ATOMIX multicentre, controlled clinical trial compared the efficacy and safety of atorvastatin and bezafibrate in patients with diet-resistant combined hyperlipidaemia. PATIENTS AND STUDY DESIGN: Following a 6-week placebo ru...